HDAC-IN-38

• UNSPSC Description:

  HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5)[1].

• Target Antigen:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/hdac-in-38.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NO)/C=C/C1=CC=C(C=C1)CNCCCN2C3=C(CCC4=C2C=C(C=C4)Cl)C=CC=C3

• Molecular Weight:

  461.98

• References & Citations:

  [1]Kaur N, et al. Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment. Eur J Med Chem. 2020 Feb 1;187:111915.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2408123-36-2